510: Creating New Compounds to Treat Central Nervous System Disorders - Dr. Al Robichaud

Summary: Dr. Al Robichaud is Chief Scientific Officer at Sage Therapeutics. The team at Sage Therapeutics is focused on delivering new medicines for people with central nervous system disorders, such as depression. The compounds they have developed modulate the activity of receptors in the brain that respond to specific neurotransmitters. Outside of science, Al has been an avid scuba diver for most of his life. He particularly enjoys exploring the ocean in the Caribbean with his family.